New France alliance to fast-track immunotherapy from lab to clinic

Partnerships between biotech companies and academic institutions are essential to advancing research and development.

Against this background, French immunotherapy company OSE Immunotherapeutics (Euronext: OSE), Inserm Transfert, and Nantes University have taken this step by announcing a new strategic collaboration to accelerate the development of immunotherapies in oncology, inflammation, and autoimmunity.

By combining academic research with industrial expertise, the partnership seeks to transform cutting-edge immunology discoveries into industrial programs capable of delivering breakthrough therapies to patients. This large-scale public–private alliance strengthens long-standing ties with the Immunotherapy Innovation Hub in Nantes and sets the stage for expanding this collaborative model nationwide in the years ahead.